Literature DB >> 15566417

Prevalence and factors associated with headache in patients with systemic lupus erythematosus.

N D Weder-Cisneros1, J F Téllez-Zenteno, M H Cardiel, M Guibert-Toledano, J Cabiedes, A L Velásquez-Paz, G García-Ramos, C Cantú.   

Abstract

Headache is common in systemic lupus erythematosus with reported prevalence as high as 70%. The aims of this study were: to estimate the prevalence and types of headache in a sample of patients with systemic lupus erythematosus comparing it with rheumatoid arthritis, to determine clinical and serological associations. Eighty-one systemic lupus erythematosus and 29 rheumatoid arthritis consecutive patients seen in our outpatient clinic were interviewed. Headache was evaluated using the diagnostic criteria proposed by the International Headache Society. Additional evaluations were carried out in the 81 systemic lupus erythematosus patients including depression, disease activity, lupus damage, function disability, quality of life, and severity degree using a validated scales. We analysed the following autoantibodies: anti-double stranded DNA, anti-nucleosomes, anti-histones, anti-ribosomal P, anti-cardiolipin antibodies, anti-beta2-glycoprotein-I (GPI), and antinuclear antibodies. Forty-one per cent of systemic lupus erythematosus and 17% of rheumatoid arthritis patients suffered from headache (P = 0.02). No significant difference for any primary headache type between the two groups was found. Frequency of headache types in systemic lupus erythematosus patients was: migraine 24%, tensional-type headache 11%, and mixed headache 5%. In systemic lupus erythematosus patients the risk factors associated with headaches were Raynaud's phenomenon (OR 3.6; 95% CI 1.3-9.5; P = 0.009) and beta2GPI antibody positivity (OR 4.5; 95% CI 1.2-16.2; p = 0.016). We conclude that headache is more common in systemic lupus erythematosus than in rheumatoid arthritis patients and was independently associated with Raynaud's phenomenon and beta2GP-I antibodies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15566417     DOI: 10.1111/j.1468-2982.2004.00822.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  6 in total

1.  Prevalence and classification of headache in patients with systemic lupus erythematosus.

Authors:  Bruno Lessa; Alex Santana; Isabella Lima; José Martônio Almeida; Mittermayer Santiago
Journal:  Clin Rheumatol       Date:  2006-01-26       Impact factor: 2.980

2.  [Primary headaches and the influence of inflammatory diseases of the CNS and their respective immunmodulatory therapy].

Authors:  M Empl; A Straube
Journal:  Schmerz       Date:  2007-10       Impact factor: 1.107

Review 3.  Novel insights into associations of antibodies against cardiolipin and beta2-glycoprotein I with clinical features of antiphospholipid syndrome.

Authors:  O Shovman; B Gilburd; O Barzilai; P Langevitz; Y Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2007-04       Impact factor: 8.667

4.  Case reports on two patients with episodic vertigo, fluctuating hearing loss and migraine responding to prophylactic drugs for migraine. Menière's disease or migraine-associated vertigo?

Authors:  R Teggi; B Fabiano; P Recanati; P Limardo; M Bussi
Journal:  Acta Otorhinolaryngol Ital       Date:  2010-08       Impact factor: 2.124

5.  Comorbidities of migraine.

Authors:  Shuu-Jiun Wang; Ping-Kun Chen; Jong-Ling Fuh
Journal:  Front Neurol       Date:  2010-08-23       Impact factor: 4.003

6.  H-magnetic resonance spectroscopy: diagnostic tool in recurrent headache in systemic lupus erythematosus. A case report.

Authors:  Emanuele Tinelli; Simona Pontecorvo; Manuela Morreale; Francesca Caramia; Ada Francia
Journal:  Radiol Case Rep       Date:  2018-11-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.